First Trust Dorsey Wright Momentum & Dividend Etf (DDIV)
- 46.329
- +0.172+0.37%
First Trust Dorsey Wright Momentum & Dividend Etf (DDIV) News
Day 3 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Intensive talks on new "-tinib" drugs as star companies such as BeiGene and Kelun Biotech take the stage.
1) Intensive negotiations for new "-tinib" class drugs took place in the morning, with innovative pharmaceutical companies such as InnoCare Pharma, Shouyao Holdings, and Jiangsu Wellshine making successive appearances; 2) In the afternoon session, leading pharmaceutical firms including Kelun Biotech and BeiGene were featured, engaging in a two-pronged strategic dynamic in the ADC sector characterized by "expansion within the catalog" and "new additions outside the catalog."
These S&P 500 Utilities Stocks Trade Below Their 200-day Average
Trending Stocks This Week as Markets Weigh Jobs Data and Rates
Utilities Sector Underperforms In August; Constellation Energy Gains, PG&E Declines
Musk Warns of AI Power Shortfall! Global Surge in Grid Construction Sparks Investment Opportunities in Computing-Power Synergy
The rapid development of AI is driving unprecedented electricity demand, making the urgent expansion and upgrading of global power grids imperative.
Blackstone and Cliffwater’s private equity funds have again triggered the 5% redemption cap, while new fundraising in the industry plummeted by 82% this year.
Blackstone’s $77 billion flagship private credit fund, BCRED, and the $31 billion Cliffwater flagship fund both hit their 5% redemption caps again in the third quarter, with redemption requests reaching 10% for the former and 16% for the latter. The industry-wide backlog of approximately $15 billion in redemptions remains difficult to resolve in the short term, while fundraising for non-traded business development companies (BDCs) plummeted by 82% this year.
AbbVie Touts Positive Data For Multiple Myeloma Drug
AbbVie Inc. (NYSE:ABBV) on Thursday reported topline outcomes from its Phase 3 CERVINO trial evaluating etentamig, an investigational treatment for relapsed or refractory multiple myeloma.The study
S&P 500 Gainers: Today's Top Performers Ranked by Quant
AbbVie Succeeds in Late-stage Trial for Multiple Myeloma Drug
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Thursday.Shares of Summit Therapeutics Inc (NASDAQ:SMMT) rose sharply during Thursday's session after the company
At the G20 Summit, tech leaders focus on AI infrastructure bottlenecks in “power” and “talent.”
Musk explicitly pointed out that the electricity shortfall for AI chips will reach at least 15 gigawatts by 2027, with chip production capacity growing by 40%-50% annually while power supply increases by only 10%-20%. Google and Anthropic have already leased computing power from SpaceX, primarily because SpaceX has taken the lead in breaking through constraints by building its own power plants. Meanwhile, Zuckerberg stated that the shortage of "hundreds of thousands or even millions" of skilled positions required for data center construction is difficult to fill.
Nvidia Jumps On AI Bid, Software Stocks Dip: Stock Market Today
U.S. equities clawed back ground Wednesday, with the S&P 500 up 0.5% as a fresh wave of artificial intelligence dealmaking offset an ugly session for high-multiple software and cybersecurity stocks.
10 Financial Stocks With the Biggest Year-over-year CapEx Growth
This Toast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings
30 Large-cap Stocks Flashing Strong Buy Rating
California Assembly to Adjourn Without Voting on Wildfire Bill
This PG&E Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings
B of A Securities Downgrades Edison International to Neutral, Lowers Price Target to $51
B of A Securities analyst Ross Fowler downgrades Edison International (NYSE:EIX) from Buy to Neutral and lowers the price target from $81 to $51.
California Lawmakers Set to Vote on Wildfire Liability Bill
GoPro, Tesla, SanDisk, Nio and Edison International: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices ended lower on Monday, with the Dow Jones Industrial Average falling 0.7% to 53,185.90, the S&P 500 declining 0.33% to 7,786.14 and the Nasdaq ending flat at 26,370.88.Despite the